University of Luxembourg celebrates 15 years of brain research

Founded in 2009, the Luxembourg Centre for Systems Biomedicine (LCSB) is celebrating 15 years of contribution to biomedical research in Luxembourg and beyond. Focusing on neurodegenerative disorders since its creation, the centre put Luxembourg on the map for its internationally recognised Parkinson’s research, developed a strong expertise in bioinformatics and kept expanding its range over the years.

Today, the LCSB 17 research groups gather scientists with diverse academic backgrounds from over 50 different countries to study the brain and its diseases. In an effort to better understand neurodegeneration, its underlying mechanisms and its impact, LCSB researchers explore topics such as neuroinflammation, cell metabolism, the gut microbiome and the influence of chemical pollution on human health. Their ultimate aim: to find new ways to prevent and treat neurological disorders, from Alzheimer’s and Parkinson’s to epilepsy and rare childhood diseases.

“Fifteen years ago, the LCSB started as a blank canvas. It was very exciting to have the opportunity to build something from scratch and to have a vision for the future of science in this country,” recalls Dr Françoise Meisch, strategic advisor at the LCSB. “What began as a small group of motivated scientists under the leadership of Prof. Rudi Balling has now turned into a fully-fledged research centre with 270 members, some significant scientific results to its credit and projects, such as the National Centre of Excellence in Research on Parkinson’s disease (NCER-PD) or the Scienteens Lab, that have a direct impact on society. I think we can be proud!”

After dedicating much of its scientific expertise to the fight against COVID-19, the LCSB welcomed the end of the pandemic with the arrival of Prof. Michael Heneka as its new director. To bring neurodegenerative processes and their shared mechanisms in the spotlight once more, Prof. Heneka is building a long-term strategy for the centre based on strong international collaborations and interdisciplinary projects. “Neurogenerative diseases are on the rise, affecting millions worldwide. Developing better preventive strategies and finding effective treatments is crucial. To this end, we want to foster cutting-edge research with an impact, train a next generation of bold researchers and encourage multidisciplinary approaches,” he details. “We will also venture into new topics such as autism and amyotrophic lateral sclerosis, to keep searching for common features when it comes to brain diseases and to use these synergies for the benefits of the patients.”

While the LCSB celebrated its 10th anniversary with a bang, a public exhibition of ten massive brain sculptures disseminated throughout Luxembourg city, the 15-year festivity was a family affair: the LCSB team gathered to look back, look forward and enjoy some well-deserved cake. This get-together was also the opportunity to fill a time capsule with meaningful souvenirs, creating a snapshot of life at the LCSB in 2024. The capsule, to be opened in 2039, will be displayed for the next 15 years in Biotech 3, the new building being constructed on campus Belval that will soon provide additional space for biomedical research in Luxembourg.

This article was first published on 25 September by University of Luxembourg.